Stocks in Analyst Viewfinder: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Analysts on the sell-side are offering a consensus “Buy” rating on shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).  Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.70 on the shares.  Based on a recent trade, the shares are hovering around $2.90 which, according to the Street, yields significant upside potential to the $9.58 consensus price target

Investors may be trying to decide if the current market environment remains bullish. It can be extremely difficult to decide when to sell, especially when data seems positive and most signs are pointing higher. Jumping in to buy stocks on a pullback may seem like a good idea, but following specific sectors may become increasingly more important. Following long-term trends may help the investor see the bigger picture of what has been going on with a specific stock or sector. Deciding to sell a winner after a big run can be tempting, but knowing the underlying causes for the run may help identify if there may indeed be more room for gains. Avoiding common investing pitfalls may take many years to master, but it may end up determining long-term success.  

Wall Street firms hire hundreds of analysts who provide recommendations on stocks.  Typically, these analysts look at a company’s fundamentals, building financial models from this information in order to project future trends, specifically future earnings. 

These projections are then used as a basis for providing “buy” or “sell” recommendations.  Many investors consider these recommendations very seriously, and often times whenever an analyst changes their outlook on a stock, the price change almost immediately.

Many investors get into the stock market with unrealistic expectations. For whatever reason, they may have the mindset that snatching profits is easy. Thinking that profits can be doubled or tripled right away may lead the investor down the road of no return. Although the lucky few might hit some big winners right off the bat, these chances are quite low. Stocks tend to be volatile in the short-term. Unless investors have a game plan ready to capitalize on short-term movements, they may want to take a wider, longer-term approach. Trying to figure out which way the market will turn from one day to the next can be a highly frustrating procedure. Having the patience to thoroughly examine every trade can immensely boost the investor’s chances of surviving and thriving into the future.

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will “beat” the artificially lowered estimate in order to get inexperienced investors to buy.

RSI 

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)’s shares may have a significant upside to the consensus target of 9.58, but how has it been performing relative to the market?  The stock’s price is 2.90 and their relative strength index (RSI) stands at 55.98.  RSI is a technical oscillator that shows price strength by comparing upward and downward movements.  It indicates oversold and overbought price levels for a stock.  

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares are moving -2.68% trading at $2.90 today,

Investors may be trying to decide if the current market environment remains bullish. It can be extremely difficult to decide when to sell, especially when data seems positive and most signs are pointing higher. Jumping in to buy stocks on a pullback may seem like a good idea, but following specific sectors may become increasingly more important. Following long-term trends may help the investor see the bigger picture of what has been going on with a specific stock or sector. Deciding to sell a winner after a big run can be tempting, but knowing the underlying causes for the run may help identify if there may indeed be more room for gains. Avoiding common investing pitfalls may take many years to master, but it may end up determining long-term success.  

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*